About Curoverse
Curoverse is a Healthcare company based in Boston (United States) founded in 2010, and was acquired by Veritas Genetics in August 2017. Genomic and biomedical Big Data infrastructure is provided. It operates in the Healthcare and Technology sectors. Curoverse has raised $1.7 million across 3 funding rounds from investors including Veritas Genetics, HHS and Hatteras Venture Partners. Curoverse offers products and services including Arvados. Its focus areas include Enterprise Infrastructure, Open Source, Healthcare and Life Sciences and Life Sciences. Its legal entity is GorillaSpace Pte. Ltd. Its competitors include Helix, Benchling and Genuity Science; 3 of its 3 listed competitors have raised funding.
Company details
Curoverse was founded in 2010 in Boston, United States, within the genomic and biomedical sector. Open source software is utilized entirely in its platform. Arvados, a free and open source system originally developed for the Harvard Personal Genome Project, forms its core. Data management, computation, and sharing needs specific to genomic and biomedical data are handled through this infrastructure, supporting research operations across the field.
- Headquarters Boston, United States
- Stage Acquired
- SectorsHealthcareTechnology
- Website curoverse.com
- Social LinkedIn X Facebook
- Acquired by Veritas Genetics (Aug 2017)
- Legal Name Gorillaspace Pte. Ltd
- Total Equity Funding$1.7M (USD)
in 3 rounds
- Latest Funding Round$500K (USD), Debt – Conventional
Mar 2015
- InvestorsVeritas Genetics
& 6 more
- Acquired byVeritas Genetics
(Aug 2017)
Products & Services of Curoverse
Curoverse offers a comprehensive portfolio of products and services, including Arvados.
Platform for managing and processing large biomedical data sets securely.
Funding Insights of Curoverse
Curoverse has successfully raised a total of $1.7M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $500 thousand completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.7M
- Total Rounds 3
- Last Round Debt – Conventional — $500,000
- First Round $1.7M
(Feb 2014)
- Investors Count 6
All 3 funding rounds of Curoverse with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2015 | $500,000 | Debt – Conventional | – | – | – |
| Sep 2014 | $1.8M | Grant | – | – | |
| Feb 2014 | $1.7M | Seed | – | – |
7 investors in total: 7 institutional.
Investors in Curoverse
Curoverse has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Veritas Genetics, HHS and Hatteras Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | hatterasvp.com | Durham, United States | ||
Tech focused early stage VC firm investing in the US | mass-ventures.com | Boston, United States | ||
| bostonglobalventures.com | ||||
Seed and early-stage investments in US tech sectors are made. | pjc.vc | Boston, United States | ||
Converge is engaged in venture capital investments for technology startups. | converge.vc | Cambridge, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Genetic testing products for health risks and traits are offered. | 2014 | veritasgenetics.com | Danvers, United States |
Investor details for Curoverse
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Curoverse
4 dated milestones of Curoverse across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Curoverse is founded.
- Funding First funding round of $1.7M.
- Funding Latest funding round, Debt – Conventional, of $500K.
- Exit Acquired by Veritas Genetics.
Competitors of Curoverse
Curoverse has 3 listed competitors in our database, 3 of them funded. They include Helix, Benchling and Genuity Science.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. | |
| genuitysci.com | 2013 | Boston, United States | $515M | AI-based omics data analysis solutions are provided to researchers. |
Detailed competitors of Curoverse
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Curoverse (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Curoverse
Complete news archive for Curoverse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Curoverse
Curoverse was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Curoverse is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Curoverse is a funded company, having raised a total of $1.7M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.7M, raised on Feb 2014.
Curoverse was founded in 2010 in Boston, United States, within the genomic and biomedical sector. Open source software is utilized entirely in its platform. Arvados, a free and open source system originally developed for the Harvard Personal Genome Project, forms its core. Data management, computation, and sharing needs specific to genomic and biomedical data are handled through this infrastructure, supporting research operations across the field.
Curoverse's top competitors include Helix, Benchling and Genuity Science.
Curoverse offers Arvados.
Curoverse has 7 investors. Key investors include Veritas Genetics, HHS, Hatteras Venture Partners, MassVentures, and Boston Global Ventures.
Curoverse operates through Gorillaspace Pte. Ltd.
Yes. Curoverse was acquired by Veritas Genetics in August 2017.